Login to Your Account



Merck snags Rigontec for $137M up front, $416M in milestones

By Cormac Sheridan
Staff Writer

Wednesday, September 6, 2017

DUBLIN – Merck & Co. Inc. is paying €115 million up front and up to €349 million more in milestones to acquire Rigontec GmbH, which is developing an RNA-based immuno-oncology therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription